Sennoside B
Based on 3 publication(s) in Google Scholar
Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.23%
- CAS No.: 128-57-4
- Formule: C42H38O20
- Masse moléculaire:862.74
-
Stockage:
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sennoside B
More
Activité biologique
Sennoside B increases prostaglandin E2 (PGE2) levels and inhibits H+/K+-ATPase[1].
Sennoside B (50, 100 µM) increases the concentration of PGE2 to 105.4 pg/mL and 173.6 pg/mL in AGS gastric cells at doses of 50 μM and 100 μM, respectively[1].
Sennoside B (0, 10, 100, 1000 nM) decreases the expression of PDGF-BB-induced phosphorylation of PDGFR-β, STAT-5, AKT and ERK in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MG63 cells
-
Concentration:0, 10, 100, 1000 nM
-
Incubation Time:
-
Result:Resulted in a marked inhibition of PDGF-BB-induced PDGFR-β phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:170-200g, Male Sprague-Dawley rats (HCl•EtOH-induced gastritis)[1]
-
Dosage:100 mg/kg
-
Administration:P.o.
-
Result:Reduced lesion indices to 60.8 ± 18.4 mm, by inhibition rate of 39.9%.
Chemical Information
-
CAS No. 128-57-4
-
Appearance Solid
-
Masse moléculaire 862.74
-
Formule C42H38O20
-
Color Light yellow to yellow
-
SMILES
O[C@@H]1[C@@H](O)[C@H](OC2=C(C(C(C(O)=CC(C(O)=O)=C3)=C3[C@]4([C@@]5(C(C=CC=C6O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)=C6C(C8=C5C=C(C(O)=O)C=C8O)=O)[H])[H])=O)C4=CC=C2)O[C@H](CO)[C@H]1O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Host Microbe
Mycobacterium tuberculosis suppresses host DNA repair to boost its intracellular survival. [Abstract]2023 Nov 8;31(11):1820-1836.e10. PMID: 37848028 -
J Enzyme Inhib Med Chem
Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]2025 Dec;40(1):2501743. PMID: 40371698 -
Pathol Res Pract
Sennoside B inhibits malignant phenotypes of triple-negative breast cancer cells and represses ERK/AKT/STAT5 signaling. [Abstract]2025 May:269:155842. PMID: 40043522
Solvant et solubilité
DMSO : 100 mg/mL (115.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hwang IY, et al. Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase. Biomol Ther (Seoul). 2015 Sep;23(5):458-64. [Content Brief]
[2]. Chen YC, et al. Sennoside B inhibits PDGF receptor signaling and cell proliferation induced by PDGF-BB in human osteosarcoma cells. Life Sci. 2009 Jun 19;84(25-26):915-22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1591 mL | 5.7955 mL | 11.5910 mL | 28.9774 mL |
| 5 mM | 0.2318 mL | 1.1591 mL | 2.3182 mL | 5.7955 mL | |
| 10 mM | 0.1159 mL | 0.5795 mL | 1.1591 mL | 2.8977 mL | |
| 15 mM | 0.0773 mL | 0.3864 mL | 0.7727 mL | 1.9318 mL | |
| 20 mM | 0.0580 mL | 0.2898 mL | 0.5795 mL | 1.4489 mL | |
| 25 mM | 0.0464 mL | 0.2318 mL | 0.4636 mL | 1.1591 mL | |
| 30 mM | 0.0386 mL | 0.1932 mL | 0.3864 mL | 0.9659 mL | |
| 40 mM | 0.0290 mL | 0.1449 mL | 0.2898 mL | 0.7244 mL | |
| 50 mM | 0.0232 mL | 0.1159 mL | 0.2318 mL | 0.5795 mL | |
| 60 mM | 0.0193 mL | 0.0966 mL | 0.1932 mL | 0.4830 mL | |
| 80 mM | 0.0145 mL | 0.0724 mL | 0.1449 mL | 0.3622 mL | |
| 100 mM | 0.0116 mL | 0.0580 mL | 0.1159 mL | 0.2898 mL |
Sennoside B Related Classifications
HY-N0366 Related Classifications
Powered by Bioz